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Nonadherence to oral antihyperglycemic agents (OHAs) leads to
an increase in use of health care resources and overall expendit-
ures due to type 2 diabetes and its complications. People with type
2 diabetes are almost twice as likely to have anxiety and depres-
sion as the general population. Our aim was to examine health care
costs associated with adherence to OHAs and the effect of depres-
sion and anxiety disorders on these in older adults with type 2 dia-
betes.
Methods
We used data from a representative sample (N = 2,811) of com-
munity-dwelling adults in Quebec aged 65 years or older who par-
ticipated in the Étude sur la Santé des Aînés survey. The final
sample consisted of 301 participants who were diagnosed with
type 2 diabetes and who were taking OHAs. Total  health care
costs were calculated as the sum of the costs of hospitalizations
and outpatient clinic services. Adherence to OHAs was measured
using the medication possession ratio. Depression and anxiety dis-
orders were assessed using criteria from the Diagnostic and Stat-
istical Manual of Mental Disorders, 4th Edition. We also analyzed
data by the Charlson Comorbidity Index, age, sex, education, and
marital status, using generalized linear models.
Results
Nonadherence among people without depression or anxiety was
associated with higher total health care costs ($4,477; 95% confid-
ence interval [CI], $3,754–$5,201; P < .001), as was nonadher-
ence among people with depression or anxiety ($11,124; 95% CI,
$9,685–$12,562; P < .001).
Conclusion
Improving adherence to OHAs among people with type 2 diabetes,
particularly those with underlying mental disorders such as de-
pression or anxiety, can decrease health care costs.
Introduction
The prevalence of diabetes is increasing worldwide and is a grow-
ing public health concern among older adults (1). According to the
Public Health Agency of Canada, diabetes affects more than 20%
of Canadian adults aged 65 or older (2); medication adherence is
crucial for improving clinical outcomes and reducing the social
and economic burden (3). The main consequence of poor adher-
ence to oral antihyperglycemic agents (OHAs) is decreased gly-
cemic control, leading to diabetes-related complications, includ-
ing microvascular and macrovascular diseases (4).
In the United States in 2012, as much as $105 billion in avoidable
health care costs was attributed to nonadherence to medications
for 6 diseases: hypercholesterolemia, hypertension, type 2 dia-
betes, osteoporosis, HIV, and congestive heart failure. However,
type 2 diabetes and hypercholesterolemia have the highest impact
on avoidable health care costs (5). Medication nonadherence is a
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common problem among older adults with diabetes (6); in a Cana-
dian study, the rate was 86% (7). The literature suggests a direct
relationship  between  medication  adherence  to  hypoglycemic
agents and improved glycemic control and reduced health care
costs (8,9). Nonadherence leads to an increase in health care re-
source use and overall expenditure due to diabetes and its com-
plications (3,10).
Furthermore, people with diabetes are almost twice as likely to
have anxiety and depression as the general population (11,12).
Both depression and anxiety are associated with poor adherence or
to medications in chronically ill  patients (6).  Total health care
costs for people with diabetes and depression are estimated to be
as much as 4.5 times higher than for people with diabetes alone
(13).
Little is known about the effect of mental disorders on medication
adherence in relation to health care costs in older adult popula-
tions with diabetes. The objective of this study was to examine
health care costs from a health care system perspective among
people with depression and/or anxiety and the effect of these ill-
nesses on adherence to OHAs in older adults with type 2 diabetes
in a publicly managed health care system.
Methods
Data used in this study originated from the longitudinal Quebec
Survey on Seniors’ Health (Étude sur la Santé des Aînés [ESA]).
The ESA was conducted from 2005 through 2008 using a probab-
ilistic sample of French-speaking community-dwelling adults aged
65 years  or  older  (N = 2,811);  94% of the Quebec population
speaks French. Potential participants living in northern regions of
Quebec, Canada, were excluded on feasibility grounds; in 2005,
10% of the older Canadian population resided in these regions.
The sampling frame was stratified by 3 geographic areas: metro-
politan, urban, and rural. A proportional sample of households was
then constituted according to the 16 health administrative regions
of Quebec. A random sampling method was also used to select
only 1 older adult  (aged ≥65 y) in the household.  The partici-
pation rate in the ESA survey was 76.5%. The project was re-
viewed and authorized by the ethics committee of the Sherbrooke
Geriatric University Institute.
Procedure
The in-home interviews, which lasted 90 minutes on average, were
conducted by health professionals who received a 2-day training.
Because memory problems may affect the accuracy of responses
to the ESA questionnaire (ESA-Q) and performance on psycholo-
gical questionnaires, people who obtained a score of less than 22
on the Mini-Mental State Examination were excluded (n = 27) at
the beginning of the interview (14–16). Thereafter, people having
no moderate or severe cognitive problems were invited to respond
to the ESA-Q (n = 2,784). At the end of the interview, respond-
ents were asked to give written consent,  allowing the research
team to access their health and pharmaceutical services data from
the Régie d’Assurance Maladie du Québec (RAMQ),the agency
responsible for Quebec’s health insurance plan.
Using the participant’s health insurance number, we linked the
ESA survey and individual-level information from the RAMQ’s
medical and pharmaceutical service databases and the health min-
istry’s  MED-ECHO (Maintenance et  exploitation des données
pour l’étude de la clientèle hospitalière) database on hospitaliza-
tions. Information on pharmaceutical services included the dis-
pensed drug’s code, quantity, dosage, and length of treatment and
the date the drug was dispensed to respondents. The RAMQ physi-
cian services database contains data on claims and physician fees
paid for consultations and medical services rendered. Data were
matched for  2,494 of  2,504 (99.6%) study participants.  Parti-
cipants with private drug insurance plans were excluded (n = 208),
because medications delivered to these participants are not re-
gistered in the RAMQ pharmaceutical registry under the public
drug insurance plan. The study sample consisted of 2,286 patients
aged 65 years or older for whom RAMQ and MED-ECHO data
were available.
For this study, patients with type 2 diabetes were identified ac-
cording to criteria used in the National Diabetes Surveillance Sys-
tem (2). People were considered to have type 2 diabetes if they
had 2 physician visits on 2 different days within any contiguous
730-day period or 1 hospitalization with a discharge diagnosis of
diabetes mellitus code 250 from the International Classification of
Diseases, 9th Revision (ICD-9) or the International Classification
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM).
Only  patients  taking  oral  hypoglycemic  medications  were  in-
cluded; the final sample for analysis consisted of 301 patients re-
ceiving oral hypoglycemic pharmacotherapy. A preliminary ana-
lysis showed that the presence of mental disorders was not associ-
ated with the switching of medication or use of hypoglycemic
polytherapy (Fisher exact test, P > .05).
Measures
Independent variable
Medication adherence was measured using the medication posses-
sion ratio (MPR) (17).  The MPR was calculated over a 1-year
period for patients taking any oral antidiabetic medications or a
combination of these medications. The MPR (%) was calculated
as the total day’s supply of medication divided by the number of
days in the evaluation period, multiplied by 100 ([total day’s sup-
PREVENTING CHRONIC DISEASE VOLUME 12, E230
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   DECEMBER 2015
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
2       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2015/15_0412.htm
ply of medication/no. of days in evaluation period] × 100). The
variable medication adherence was dichotomized (MPR ≥80% vs
MPR <80%), as has been proposed (18). Six participants had only
a 6-month follow-up period and were categorized as nonadherent.
The  respondent’s  mental  health  condition  was  measured  at
baseline using the diagnostic module of the ESA-Q based on cri-
teria of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) (19–21). The ESA-Q is similar to the Diagnostic Inter-
view Schedule and Composite International Diagnostic Interview,
which demonstrated good reliability  and validity  (22).  In  this
study, a DSM-IV diagnosis over a 12-month period was made for
the  following  disorders:  major  depression,  minor  depression,
mania, specific phobia, social phobia, agoraphobia, panic disorder,
obsessive-compulsive disorder, and generalized anxiety disorder.
Complete definitions of the disorders studied in the ESA are avail-
able (23). For the analysis, respondents were classified as 1) hav-
ing at least 1 probable DSM-IV disorder (depressive or anxiety
disorder) or 2) not having a probable DSM-IV disorder (depress-
ive or anxiety disorder) during the 2-year study period.
The respondent’s physical health condition was measured using
the Charlson Comorbidity Index (24).  This index has a strong
monotonic association of an approximate twofold increase in mor-
tality per increment in index level. This index was calculated us-
ing medical claims with ICD-9-CM codes for the 12-month peri-
od before the interview date and excluded diagnoses related to
type 2 diabetes. Other study variables were education (<10 y and
≥10 y), marital status (married or living as a couple, and single/
separated/divorced/widowed), age (65–74 y and ≥75 y), and sex.
Dependent variable
Our cost analyses took the perspective of Quebec’s public health
care system. The calculation of unit costs (in Canadian dollars)
was based on summary annual reports for the province of Quebec
using a direct allocation method (25). Total health care costs in-
cluded costs related to hospitalizations, ambulatory visits (outpa-
tient clinic visits and emergency department visits), physician fees,
and outpatient medications for a 1-year follow-up. The method
used to calculate unit and overall health care costs has been de-
scribed (26). Briefly, unit costs were based on data in the Quebec
Ministry of Health and Social Services annual budget and the AS-
471 and AS-478 financial and statistical reports produced by all
institutions in the province of Quebec. The cost of hospitaliza-
tions was calculated per diem; emergency department visits and
outpatient visits in nonprivate offices (ie, public institutions) were
valued at  cost  per  visit.  Average provincial  costs  and activity
levels for the 2009 and 2010 fiscal years were used.
Analyses
Data were weighted to ensure that the true proportions of older
adults in each geographic area were reflected. The mean and medi-
an sampling design effects were 0.94 and 0.95, respectively. De-
scriptive analyses were conducted to examine the characteristics of
participants. Generalized linear regression models with a γ distri-
bution and log link were used to estimate the association between
health care costs and type of costs (ambulatory, in-patient, physi-
cian fees, medication) and the possible interaction between medic-
ation adherence and the presence of common mental disorders (de-
pression or anxiety).
Dummy variables were created in which comparisons were pos-
sible between 1) adherent participants without depression and/or
anxiety, 2) nonadherent participants without depression and/or
anxiety, 3) adherent participants with depression and/or anxiety, 4)
nonadherent participants with depression and/or anxiety. To con-
trol for confounding, we adjusted the model for age, sex, marital
status,  education,  and  severity  of  physical  health  conditions
(Charlson Comorbidity Index) and OHA exposure in previous
year. Statistical significance was set at P < .05. Data were ana-
lyzed using SAS version 9.1 for Windows (SAS Institute, Inc).
Results
In  this  population-based  study,  301  (13.2%)  participants  dia-
gnosed with type 2 diabetes were taking OHAs (Table 1). Most of
these participants were adherent (74.4%). Adherent participants
were less likely (odds ratio [OR], 0.49; 95% CI, 0.25–0.94) than
nonadherent participants to have a probable depression and/or
anxiety disorder. Health care costs by adherence and study vari-
ables are presented in Table 2.
Unadjusted estimates (Table 3) showed that nonadherent parti-
cipants with and without depression and/or anxiety incurred on av-
erage higher total health care costs ($14,979 and $9,008, respect-
ively) than did adherent participants with and without depression
and/or anxiety ($6,256 and $5,428, respectively).
After adjustment for study variables (Table 4), among participants
without depression/anxiety, nonadherence (vs adherence) was as-
sociated  with  higher  total  health  care  costs  ($4,447;  95% CI,
$3,754–$5,201).  Among respondents  with  depression/anxiety,
nonadherence  (vs  adherence)  was  also  associated  with  higher
health care costs (absolute difference, $11,124; 95% CI, $9,685 -
$12,562). Furthermore, nonadherent participants reporting depres-
sion/anxiety incurred higher total health care costs ($11,860; 95%
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CI, $10,697–$13,023) than adherent participants without depres-
sion/anxiety. Higher total costs were driven by higher ambulatory
and inpatient-related costs, physician fees paid out, and medica-
tion costs.
Discussion
This is one of the first studies to assess, in a publicly managed
health care system, the impact on health care system costs of ad-
herence to OHAs and the presence of depression and/or anxiety in
a representative sample of community-dwelling older adults with
type 2 diabetes. This study linked health survey data collected dur-
ing in-home interviews, assessing the presence of probable mental
disorders and sociodemographic and economic factors, to health
administrative data from the RAMQ on medical and pharmaceut-
ical services use. This linkage increased the validity of results by
reducing recall bias on health services use and controlling for vari-
ous confounding variables.
In this study, 74.4% of participants with type 2 diabetes were ad-
herent to their OHAs; this percentage is similar to a previously re-
ported adherence rate (86%) among older adults taking the same
type of drug over a 3-year period in Canada (7).
Our findings showed a differential association between medica-
tion adherence and the presence of common mental disorders in
terms of total health care costs. These results are consistent with
previous findings reporting that increased adherence was associ-
ated with lower total annual health care costs among adults (3).
Similarly, one systematic review reported that low medication ad-
herence in the population with diabetes was associated with great-
er health care costs (10). Studies have also reported that the pres-
ence of depression in people with diabetes is associated with high-
er total health care costs (13). In our study, nonadherence among
people without  depression/anxiety was associated with higher
health care costs ($4,477). Among people with depression/anxiety,
nonadherence was also associated with a greater effect on total
health care costs (absolute difference, $11,124). When comparing
adherent people without depression/anxiety to nonadherent people
with depression and/or anxiety,  we found greater costs among
those with depression/anxiety ($11,860).
When examining health  care  costs,  we showed an association
between physician fees paid out and ambulatory, inpatient, and
medication-related costs and adherence with and without depres-
sion and/or anxiety. Previous reports have similarly shown higher
ambulatory, inpatient, and total health care costs among a nonad-
herent population compared with an adherent one (9,10,27). Hep-
ke et al, using private insurance health employer data in a large
population of people with diabetes aged 65 years or older, indic-
ated that any potential cost savings associated with adherence to
medication were offset by increased pharmaceutical costs (27).
That adherent people had lesser costs in our study may be in part
because Quebec has a publicly managed health care system in
which most of the older adult population is covered under the pub-
lic drug insurance plan, and this health policy may have a favor-
able effect on medication adherence to OHAs and, thus, result in
decreased overall health care costs.
Our study has limitations. The medication adherence measure was
based on delivered medications. Therefore, this measure is subject
to the assumption that a prescription filled equals a prescription
taken. However, administrative databases are particularly suited
for the evaluation of medication for long-term therapy (28). As
mentioned, people using insulin therapy were excluded from this
study, because the pharmacy records do not contain information
on the variability of insulin regimens on a day-to-day basis. There-
fore, nonadherence and health care costs may have been underes-
timated. Furthermore, this study was conducted in Quebec, which
has a public health care system, so findings may not be generaliz-
able to those of other health care systems. Nevertheless, the pat-
terns of adherence were similar to those reported in other studies.
Finally, the study population was restricted to a representative
sample of French-speaking older adults in Quebec and excluded
Inuit and Cree populations living in northern regions of Quebec,
whose prevalence rates for diabetes are 3 to 5 times those of the
general population (29). The results, therefore, may not apply to
these groups.
Greater attention should be given to improve medication adher-
ence among patients with diabetes, because nonadherence is asso-
ciated with higher health care use and costs. More attention should
be given to underlying mental disorders such as depression and
anxiety. Furthermore, it is important to consider depression and
anxiety in the prevention and treatment of diabetes in the elderly
population. Poor glycemic control is often a cause of diabetes-re-
lated complications, which is an important component of addition-
al direct medical costs of treating people with type 2 diabetes.
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(n = 77), n (%)
Participants MPRa ≥80%
(n = 224), n (%)
Odds Ratio (95%
Confidence Interval) χ2b P Value
Age, y
65–74 39 (50.6) 90 (40.2) 1 [Reference]
2.56 .11
≥75 38 (49.4) 134 (59.8) 1.53 (0.90–2.57)
Sex
Male 24 (31.2) 82 (36.6) 1 [Reference]
0.74 .39
Female 53 (68.8) 142 (63.4) 0.78 (0.45–1.36)
Marital status
Married/living as a couple 31 (40.3) 104 (46.4) 1 [Reference]
0.88 .35
Single/divorced/separated/widowed 46 (59.7) 120 (53.6) 0.78 (0.46–1.31)
Education, y
<10 19 (24.7) 70 (31.2) 1 [Reference]
1.22 .27
≥10 58 (75.3) 154 (68.7) 0.72 (0.4–1.3)
Probable depressive or anxiety disorder
Yes 18 (23.4) 29 (12.9) 1 [Reference]
4.73 .04
No 59 (76.6) 195 (87.1) 0.49 (0.25–0.94)
Charlson Comorbidity Index
0 49 (63.6) 155 (69.2) 1 [Reference]
0.80 .36
≥1 28 (36.4) 69 (30.8) 0.78 (0.45–1.34)
a Medication adherence was measured using the medication possession ratio (MPR). The MPR was calculated over a 1-year period for patients taking any oral anti-
diabetic medications or a combination of these medications. The MPR (%) was calculated as the total day’s supply of medication divided by the number of days in
the evaluation period, multiplied by 100 ([total day’s supply of medication/no. of days in evaluation period] × 100).
b χ2 value determined using logistic regression.
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Table 2. Average Unadjusted Health Care Costs, by Participant Characteristics and Adherence to Oral Antihyperglycemic Agents,
Quebec Survey on Seniors’ Health, Canada, 2005–2008a
Characteristic
Average Unadjusted Health Care Cost, Canadian $

















MPR <80% MPR ≥80%
Age, y





































Probable depressive and/or anxiety disorder

















a Medication adherence was measured using the medication possession ratio (MPR). The MPR was calculated over a 1-year period for patients taking any oral anti-
diabetic medications or a combination of these medications. The MPR (%) was calculated as the total day’s supply of medication divided by the number of days in
the evaluation period, multiplied by 100 ([total day’s supply of medication/no. of days in evaluation period] × 100).
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Table 3. Average Unadjusted Health Care Costs, by Adherence to Oral Antihyperglycemic Agents and the Presence of Mental Dis-










Mean Cost, Canadian $ (95% CI)
Ambulatory visits 4,058 (1,374 to 6,743) 1,304 (1,035 to 1,573) 1,656 (754 to 2,559) 2,654 (1,649 to 3,658)
Inpatient 6,351 (−858 to 13,562) 658 (426 to 891) 994 (−64 to 1,923) 2,854 (1,000 to 4,709)
Medications 3,503 (2,392 to 4,613) 2,945 (2,599 to 3,291) 3,006 (2,091 to 3,920) 2,498 (1,863 to 3,133)
Physician fees 1,066 (425 to 1,707) 520 (422 to 617) 600 (303 to 897) 1,002 (657 to 1,346)
Total costs 14,979 (8,937 to 21,021) 5,428 (4,746 to 6,109) 6,256 (4,177 to 8,335) 9,008 (6,928 to 11,088)
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Change in Cost, Canadian $ (95% Confidence Interval)
Ambulatory
visits










P valueb <.001 <.001 <.001 <.001 <.001 <.001










P valueb <.001 <.001 <.001 <.001 <.001 .60
Physician fees 596 (513 to 678) 513 (411 to 615) −28 (−119 to 63) 568 (516 to 619) 485 (406 to 564) −83 (−152 to −13)
P valueb <.001 <.001 .54 <.001 <.001 .02
Medications






−384) −65 (−175 to −45)
P valueb <.001 <.001 <.001 <.001 <.001 .24












P valueb <.001 <.001 <.001 <.001 <.001 .13
a A plus symbol indicates the presence of depression and/or anxiety; a minus symbol indicates no depression and/or anxiety. The number of patients in each group
is as follows: nonadherent with depression and/or anxiety, n = 18; nonadherent without depression and/or anxiety, n = 59; adherent with depression and/or anxi-
ety, n = 29; and adherent without depression and/or anxiety, n = 195.
b P values determined using generalized linear modeling.
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